Patients' Risk Tolerance for Non-Dietary Therapies in Celiac Disease

Abstract

Celiac disease (CD) is an autoimmune disorder mediated by an immune response to dietary gluten that affects the small intestine and leads to inflammation, malabsorption, and systemic consequences.¹ The only established therapy is strict adherence to a gluten-free diet.^2,3 Recently there has been growth in the development of novel non-dietary therapies for patients with CD,⁴ which are driven by dissatisfaction with the burden of the gluten-free diet.^5,6.